Japanese guidelines for fingolimod in multiple sclerosis

Putting into practice

Makoto Matsui, Yuko Shimizu, Hikaru Doi, Ryo Tomioka, Ichiro Nakashima, Masaaki Niino, Jun-Ichi Kira

研究成果: ジャーナルへの寄稿評論記事

3 引用 (Scopus)

抄録

Fingolimod functions as a modulator of sphingosine-1-phosphate (S1P) receptors expressed on the surface of T and B lymphocytes, leading to their internalization. Loss of S1P receptors results in sequestration of central memory T cells enriched by Th17 cells in lymph nodes. After successful treatment of an animal model of multiple sclerosis (MS), clinical trials of oral fingolimod in patients with relapsing-remitting MS showed a 60% reduction in the annualized rate of relapse. The United States Food and Drug Administration approved fingolimod as a first-line drug for MS treatment in 2010, and data have been accumulated thereafter. However, MS experts recommend that the drug should remain as a second-line option, because the long-term risks for infection and malignancy have not been fully elucidated. Also, because of different genetic backgrounds, Asian MS patients might require special attention regarding other infectious agents and secondary cancer as compared with those reported in Caucasian patients. Furthermore, some Japanese patients who developed severe symptoms were later shown to be positive for the anti-aquaporin-4 antibody. In addition, reports of some Western MS patients have noted worsening after initiation, as well as discontinuation of fingolimod treatment. Finally, the optic spinal type of MS and neuromyelitis optica spectrum disorders are more prevalent in Asian than Western countries. Thus, establishment of criteria for determining which Asian MS patients would benefit from fingolimod treatment is mandatory.

元の言語英語
ページ(範囲)34-48
ページ数15
ジャーナルClinical and Experimental Neuroimmunology
5
発行部数1
DOI
出版物ステータス出版済み - 1 1 2014

Fingerprint

Multiple Sclerosis
Guidelines
Lysosphingolipid Receptors
Aquaporin 4
Neuromyelitis Optica
T-Lymphocytes
Th17 Cells
Relapsing-Remitting Multiple Sclerosis
United States Food and Drug Administration
Therapeutics
Pharmaceutical Preparations
Fingolimod Hydrochloride
Neoplasms
B-Lymphocytes
Animal Models
Lymph Nodes
Clinical Trials
Recurrence
Antibodies
Infection

All Science Journal Classification (ASJC) codes

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology

これを引用

Japanese guidelines for fingolimod in multiple sclerosis : Putting into practice. / Matsui, Makoto; Shimizu, Yuko; Doi, Hikaru; Tomioka, Ryo; Nakashima, Ichiro; Niino, Masaaki; Kira, Jun-Ichi.

:: Clinical and Experimental Neuroimmunology, 巻 5, 番号 1, 01.01.2014, p. 34-48.

研究成果: ジャーナルへの寄稿評論記事

Matsui, Makoto ; Shimizu, Yuko ; Doi, Hikaru ; Tomioka, Ryo ; Nakashima, Ichiro ; Niino, Masaaki ; Kira, Jun-Ichi. / Japanese guidelines for fingolimod in multiple sclerosis : Putting into practice. :: Clinical and Experimental Neuroimmunology. 2014 ; 巻 5, 番号 1. pp. 34-48.
@article{1c6320ba83ef49dab5683ff37f767797,
title = "Japanese guidelines for fingolimod in multiple sclerosis: Putting into practice",
abstract = "Fingolimod functions as a modulator of sphingosine-1-phosphate (S1P) receptors expressed on the surface of T and B lymphocytes, leading to their internalization. Loss of S1P receptors results in sequestration of central memory T cells enriched by Th17 cells in lymph nodes. After successful treatment of an animal model of multiple sclerosis (MS), clinical trials of oral fingolimod in patients with relapsing-remitting MS showed a 60{\%} reduction in the annualized rate of relapse. The United States Food and Drug Administration approved fingolimod as a first-line drug for MS treatment in 2010, and data have been accumulated thereafter. However, MS experts recommend that the drug should remain as a second-line option, because the long-term risks for infection and malignancy have not been fully elucidated. Also, because of different genetic backgrounds, Asian MS patients might require special attention regarding other infectious agents and secondary cancer as compared with those reported in Caucasian patients. Furthermore, some Japanese patients who developed severe symptoms were later shown to be positive for the anti-aquaporin-4 antibody. In addition, reports of some Western MS patients have noted worsening after initiation, as well as discontinuation of fingolimod treatment. Finally, the optic spinal type of MS and neuromyelitis optica spectrum disorders are more prevalent in Asian than Western countries. Thus, establishment of criteria for determining which Asian MS patients would benefit from fingolimod treatment is mandatory.",
author = "Makoto Matsui and Yuko Shimizu and Hikaru Doi and Ryo Tomioka and Ichiro Nakashima and Masaaki Niino and Jun-Ichi Kira",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/cen3.12080",
language = "English",
volume = "5",
pages = "34--48",
journal = "Clinical and Experimental Neuroimmunology",
issn = "1759-1961",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Japanese guidelines for fingolimod in multiple sclerosis

T2 - Putting into practice

AU - Matsui, Makoto

AU - Shimizu, Yuko

AU - Doi, Hikaru

AU - Tomioka, Ryo

AU - Nakashima, Ichiro

AU - Niino, Masaaki

AU - Kira, Jun-Ichi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Fingolimod functions as a modulator of sphingosine-1-phosphate (S1P) receptors expressed on the surface of T and B lymphocytes, leading to their internalization. Loss of S1P receptors results in sequestration of central memory T cells enriched by Th17 cells in lymph nodes. After successful treatment of an animal model of multiple sclerosis (MS), clinical trials of oral fingolimod in patients with relapsing-remitting MS showed a 60% reduction in the annualized rate of relapse. The United States Food and Drug Administration approved fingolimod as a first-line drug for MS treatment in 2010, and data have been accumulated thereafter. However, MS experts recommend that the drug should remain as a second-line option, because the long-term risks for infection and malignancy have not been fully elucidated. Also, because of different genetic backgrounds, Asian MS patients might require special attention regarding other infectious agents and secondary cancer as compared with those reported in Caucasian patients. Furthermore, some Japanese patients who developed severe symptoms were later shown to be positive for the anti-aquaporin-4 antibody. In addition, reports of some Western MS patients have noted worsening after initiation, as well as discontinuation of fingolimod treatment. Finally, the optic spinal type of MS and neuromyelitis optica spectrum disorders are more prevalent in Asian than Western countries. Thus, establishment of criteria for determining which Asian MS patients would benefit from fingolimod treatment is mandatory.

AB - Fingolimod functions as a modulator of sphingosine-1-phosphate (S1P) receptors expressed on the surface of T and B lymphocytes, leading to their internalization. Loss of S1P receptors results in sequestration of central memory T cells enriched by Th17 cells in lymph nodes. After successful treatment of an animal model of multiple sclerosis (MS), clinical trials of oral fingolimod in patients with relapsing-remitting MS showed a 60% reduction in the annualized rate of relapse. The United States Food and Drug Administration approved fingolimod as a first-line drug for MS treatment in 2010, and data have been accumulated thereafter. However, MS experts recommend that the drug should remain as a second-line option, because the long-term risks for infection and malignancy have not been fully elucidated. Also, because of different genetic backgrounds, Asian MS patients might require special attention regarding other infectious agents and secondary cancer as compared with those reported in Caucasian patients. Furthermore, some Japanese patients who developed severe symptoms were later shown to be positive for the anti-aquaporin-4 antibody. In addition, reports of some Western MS patients have noted worsening after initiation, as well as discontinuation of fingolimod treatment. Finally, the optic spinal type of MS and neuromyelitis optica spectrum disorders are more prevalent in Asian than Western countries. Thus, establishment of criteria for determining which Asian MS patients would benefit from fingolimod treatment is mandatory.

UR - http://www.scopus.com/inward/record.url?scp=84895474907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895474907&partnerID=8YFLogxK

U2 - 10.1111/cen3.12080

DO - 10.1111/cen3.12080

M3 - Review article

VL - 5

SP - 34

EP - 48

JO - Clinical and Experimental Neuroimmunology

JF - Clinical and Experimental Neuroimmunology

SN - 1759-1961

IS - 1

ER -